NovoEight Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of hemophilia a, availability of recombinant factor viii products, expansion of specialty hematology centers, improved patient access to clotting therapies, growth in preventive bleeding management.

The growth in the forecast period can be attributed to increasing demand for long-acting clotting factors, rising adoption of homecare treatment models, expanding focus on personalized hemophilia care, growing healthcare investments in rare disease management, increasing patient life expectancy. Major trends in the forecast period include increasing adoption of recombinant coagulation factors, rising focus on prophylactic hemophilia treatment, growing demand for home-based infusion therapies, expansion of personalized bleeding disorder management, enhanced supply chain cold storage capabilities.

The increasing prevalence of hemophilia is expected to drive the growth of the NovoEight market in the coming years. Hemophilia is a genetic condition in which the blood fails to clot effectively, resulting in prolonged or excessive bleeding even from minor injuries. The rising prevalence of hemophilia is largely attributed to advancements in diagnostic methods, increased disease awareness, and improved reporting systems, which have led to more individuals being accurately identified and diagnosed. NovoEight supports patients with hemophilia by effectively managing and preventing bleeding episodes, improving clotting activity, lowering the risk of spontaneous bleeding, and enhancing overall mobility and quality of life. For example, in April 2025, according to Pfizer Inc., a US-based pharmaceutical and biotechnology company, the UK hemophilia A and B patient population exceeded 11,800 individuals during the 2023/24 period, highlighting a substantial and clinically significant treated population. Therefore, the rising prevalence of hemophilia is driving the growth of the NovoEight market.

The increase in healthcare expenditure is expected to further support the growth of the NovoEight market going forward. Healthcare expenditure represents the total resources allocated to healthcare services and products at regional, national, or global levels. Growth in healthcare spending is driven by aging populations, advancements in medical technologies, the increasing burden of chronic diseases, higher patient expectations, and rising costs of healthcare services. NovoEight, a recombinant factor VIII therapy for hemophilia A, contributes to more efficient healthcare spending by reducing the frequency of bleeding events, limiting the need for emergency care, supporting better long-term disease management, lowering overall treatment costs, and improving patient quality of life. For instance, in April 2025, the Office for National Statistics reported that provisional estimates indicated UK healthcare spending reached £317 billion in 2024, reflecting a 6.5% nominal increase and a 2.4% rise in real terms compared with 2023. Therefore, the increasing healthcare expenditure is driving the growth of the NovoEight market.

The growing demand for personalized medicine is expected to propel the growth of the NovoEight market in the future. Personalized medicine focuses on tailoring treatment and healthcare strategies to individual patients based on genetic, environmental, and lifestyle factors. The rising demand for personalized medicine is driven by progress in genetic research, greater awareness of individualized treatment approaches, and the need for targeted therapies that improve outcomes while minimizing side effects. NovoEight supports personalized care in hemophilia A by enabling customized dosing regimens based on each patient’s genetic profile, clinical needs, and treatment response, leading to improved therapeutic outcomes and quality of life. For example, in February 2024, the Personalized Medicine Coalition reported that the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared with six approvals in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the NovoEight market.

Major companies operating in the novoeight market are Novo Nordisk A/S.

North America was the largest region in the novoeight market in 2025. The regions covered in the novoeight market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the novoeight market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the novoEight market by increasing costs of imported recombinant proteins, sterile filling materials, cold-chain packaging, and biopharmaceutical manufacturing equipment. North America and Europe are most affected due to reliance on global biologics supply chains, while emerging markets experience pricing constraints for advanced hemophilia treatments. These tariffs can increase therapy costs and procurement complexity. However, they also encourage domestic biologics production, regional distribution hubs, and strengthened local manufacturing capabilities.

The novoeight market research report is one of a series of new reports that provides novoeight market statistics, including novoeight industry global market size, regional shares, competitors with a novoeight market share, detailed novoeight market segments, market trends and opportunities, and any further data you may need to thrive in the novoeight industry. This novoeight market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

NovoEight, also known as turoctocog alfa, is a recombinant coagulation factor VIII used to treat and prevent bleeding episodes in people with hemophilia A. Hemophilia A is a hereditary disorder marked by a deficiency of factor VIII, a vital protein required for normal blood clotting, and NovoEight helps restore clotting ability to reduce bleeding risk.

The primary indications of NovoEight include hemophilia A and use during surgical procedures. Hemophilia A is a genetic condition in which impaired blood clotting occurs due to insufficient levels of clotting factor VIII. NovoEight is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and direct sales, and it serves a wide range of end users, including pediatric and geriatric patients, hospitals or clinics, and homecare settings.

The novoeight market consists of sales of novoeight (recombinant factor VIII), novoseven (recombinant factor VII), novoeight [RFVIII] lyophilized powder, and novoeight [RFVIII] prefilled syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.